Agilent Technologies, Inc. (A) Receives “Overweight” Rating from Morgan Stanley

Agilent Technologies, Inc. (NYSE:A)‘s stock had its “overweight” rating restated by analysts at Morgan Stanley in a report issued on Tuesday, MarketBeat Ratings reports.

A has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 price objective for the company in a research report on Tuesday, October 31st. Robert W. Baird reissued a “buy” rating and set a $70.00 target price on shares of Agilent Technologies in a report on Friday, October 20th. Cowen and Company reissued a “hold” rating and set a $65.00 target price on shares of Agilent Technologies in a report on Thursday, September 28th. Jefferies Group LLC reissued a “buy” rating and set a $66.00 target price on shares of Agilent Technologies in a report on Wednesday, August 9th. Finally, BidaskClub lowered shares of Agilent Technologies from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 12th. Five equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $66.70.

Agilent Technologies (A) traded down $0.15 during mid-day trading on Tuesday, reaching $67.31. 2,042,200 shares of the company were exchanged, compared to its average volume of 1,824,496. The firm has a market cap of $21,710.52, a PE ratio of 29.46, a price-to-earnings-growth ratio of 2.64 and a beta of 1.27. Agilent Technologies has a twelve month low of $42.92 and a twelve month high of $68.67. The company has a debt-to-equity ratio of 0.39, a quick ratio of 2.76 and a current ratio of 3.22.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Tuesday, August 15th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.07. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Agilent Technologies had a net margin of 14.36% and a return on equity of 16.95%. The firm’s quarterly revenue was up 6.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.49 EPS. analysts predict that Agilent Technologies will post 2.32 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Agilent Technologies, Inc. (A) Receives “Overweight” Rating from Morgan Stanley” was reported by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.thestockobserver.com/2017/11/14/agilent-technologies-inc-a-receives-overweight-rating-from-morgan-stanley.html.

In related news, CFO Didier Hirsch sold 72,545 shares of the stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $62.38, for a total transaction of $4,525,357.10. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Michael R. Mcmullen sold 16,492 shares of the stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $65.33, for a total transaction of $1,077,422.36. Following the transaction, the chief executive officer now directly owns 211,872 shares in the company, valued at $13,841,597.76. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 152,713 shares of company stock worth $9,682,305.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Advisor Group Inc. boosted its stake in Agilent Technologies by 0.3% during the second quarter. Advisor Group Inc. now owns 3,959 shares of the medical research company’s stock worth $235,000 after acquiring an additional 10 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its holdings in Agilent Technologies by 0.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 4,658 shares of the medical research company’s stock worth $276,000 after buying an additional 35 shares during the last quarter. Veritable L.P. raised its holdings in Agilent Technologies by 0.4% during the second quarter. Veritable L.P. now owns 10,896 shares of the medical research company’s stock worth $646,000 after buying an additional 40 shares during the last quarter. Balentine LLC raised its holdings in Agilent Technologies by 2.9% during the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock worth $106,000 after buying an additional 50 shares during the last quarter. Finally, Kingfisher Capital LLC raised its holdings in Agilent Technologies by 0.3% during the second quarter. Kingfisher Capital LLC now owns 22,643 shares of the medical research company’s stock worth $1,343,000 after buying an additional 58 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply